Blue Duck provides preclinical and clinical drug development support, including specialist monitoring and clinical operations project management, according to the company.
Blue Duck’s clinical monitoring services will fall under Boyds’ regulatory and medical monitoring support services umbrella, “to strengthen its ability to identify and develop therapies that will benefit patients,” said Boyds CEO Alan Boyd in a statement.
“In addition to the regulatory, medical monitoring and product development services already offered by Boyds, our clients will now also be able to seamlessly access clinical development services which include study set-up activities, from feasibility assessments and ethics submissions, to site contract negotiations, clinical study monitoring, and clinical study project management,” he added.
Following the transaction, Blue Duck founder Dr. Karen O’Hanlon is now the director of clinical operations at Boyds.
Said Boyds, the company will “continue to build on the monitoring provision that Blue Duck has already built up in the UK, Europe, USA, Mexico and Canada.”
Boyds also earlier this year opened a new office in Dublin, Ireland, which the CEO told us at the time will serve as “a bit of an insurance policy” ahead of Brexit.